利培酮对氯氮平血浓度影响的研究

目的　了解利培酮对氯氮平血浓度的影响及二药合用的疗效与不良反应。方法　对 5 0例原服用氯氮平治疗的难治性精神分裂症患者合并利培酮治疗 ,分别于合并治疗前及后 1月、2月、3月测定氯氮平血浓度 ,同时评定PANSS ,TESS量表。结果　合用利培酮后 ,氯氮平血浓度无明显升高 ,PANSS评分明显降低(P <0 .0 1) ,TESS评分有所增加。结论　利培酮对氯氮平血浓度无明显影响 ,二药合用能增加疗效 ,不良反应有所增加。     

家族性震颤一家系五名患者及家系调查

患者男性,农民,22岁。一年前无意中发现吃饭用右手持筷夹菜时手抖,自己不能控制,但在田间劳动或做其他事情时如常。今年别人发现其有时头摇,在人多或情绪激动时摇动更明显,同时手抖也较较前加重,但仍不影响正常的劳动和生活。查体:一般内科检查无异常发现,神经系     

Effects of antipsychotic drugs on latent inhibition: sensitivity and specificity of an animal behavioral model of clinical drug action

Latent inhibition (LI) of a conditioned emotional response (CER) has been proposed as a quantitative measure of selective attention. We have assessed the parallels of the pharmacology of LI in rats with the clinical pharmacology of schizophrenia. Drug and vehicle treated rats were divided into groups and preexposed 20 times to cage illumination as a CS, or not preexposed. All groups were conditioned with 2 CS-footshock pairings. The following day CER, as measured by interruption of drinking in response to CS presentation, was recorded. LI was observed as a decreased CER in preexposed relative to non-preexposed animals. LI was enhanced by haloperidol 0.3 mg/kg after 7 or 14 daily treatments, but not after a single acute dose. Haloperidol doses of 0.3 and 0.03 mg/kg enhanced LI, while doses of 0.003 and 3.0 mg/kg had no effect. Haloperidol enhancement of LI was unaffected by the coadministration of the anticholinergic agent trihexyphenidyl. Enhancement of LI is exhibited by the antipsychotic drugs fluphenazine, chlorpromazine, thiothixene, thioridazine, mesoridazine, and metoclopramide but not clozapine. The non-antipsychotic drugs pentobarbital, imipramine, chlordiazepoxide, trihexyphenidyl, and promethazine failed to enhance LI. LI exhibits striking parallels to the clinical pharmacology of schizophrenia.Preliminary data were presented in part at the Society for Neuroscience Annual Meeting, Phoenix, AZ, 1989     

An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET

Raclopride, a highly selective D2-dopamine receptor antagonist, was administered in doses up to 4 mg b.i.d. to ten schizophrenic patients in an open label non-comparative study lasting 4 weeks. Safety, tolerability, potential antipsychotic effect, prolactin response and drug effect on plasma homovanillic acid were evaluated. Central D2-dopamine receptor occupancy was determined by positron emission tomography (PET). No major deviations were found in biochemical and physiological safety parameters. Raclopride was well tolerated. The mean BPRS score was reduced by 55% at endpoint. In the global evaluation seven patients were very much or much improved. Extrapyramidal side effects were recorded in four patients and disappeared after dose reduction or single doses of biperiden. An increase in plasma prolactin of short duration was observed in both sexes. A significant decrease of plasma HVA was obtained after 4 weeks of treatment. In two of the patients the central D2-dopamine receptors occupancy was measured using PET. The receptor occupancy was 68 and 72% which is the same as that found in patients treated with conventional neuroleptics.     

Neuropeptides: Animal behaviour and human psychopathology

Summary Animal studies have demonstrated that neuropeptides modulate nervous system functions. It has been postulated that disturbances in neuropeptide systems may be aetiological factors in psychiatric and neurological disorders. Neuropeptides related to ACTH/MSH, including ORG 2766, increase motivation and attention and facilitate recovery processes after nerve damage. These peptides may be effective during the early stage of dementia. Vasopressin and related peptides improve memory processes in animals and humans. In addition, these peptides influence social behaviour, mood and addictive behaviour. The non-opioid -type endorphins have neurolepticlike activities in animals and antipsychotic effects in a category of schizophrenic patients. Peptides related to CCK have also been found to be effective in these patients. Some neuropeptides, e.g. TRH and PLG, have been reported to exert antidepressant effects. Further research may eventually produce neuropeptides with therapeutic action in psychiatric and neurological diseases.Parts of this article were presented on the occasion of the inauguration ceremony of the Department of Psychiatry of the University of Mainz on April 2 and 3, 1987     

Decreased prefrontal 5-HT2A receptor binding in subjects at enhanced risk for schizophrenia

The brain serotonin-2A receptor (5-HT_2AR) has been implicated in both the pathology of schizophrenia and the therapeutic action of atypical antipsychotics. However, little is known about the 5-HT_2AR status before the onset of schizophrenia and before the exposure to antipsychotics. We used [¹⁸F] altanserin and positron emission tomography (PET) in a pilot study of 6 individuals suspected to be at elevated risk for schizophrenia and seven age-matched controls to test the hypothesis that regional 5-HT_2AR binding is altered in the prodromal stages of schizophrenia. Distribution volume ratios (DVRs) as a proxy for 5-HT_2AR availability were significantly reduced in prefrontal cortex regions of at-risk subjects, implicating early abnormalities of serotonergic neurotransmission that antecede the onset of schizophrenia.     

精神分裂症患者G72基因表达水平的研究

目的 本工作旨在检测精神分裂症（Schizophrenia）患者外周淋巴细胞中G72基因的表达情况，进而探讨G72基因的表达与精神分裂症的相关关系。 方法 工作在56例精神分裂症患者和84名年龄性别相匹配的对照中进行，在新鲜外周血样本中抽提总RNA，反转录成cDNA，基因表达量的检测在ABI Prism7900HT型序列监测系统上进行，采用TaqMan的方法对患者及对照组样本的mRNA进行定量，采集的荧光数据经SDS2.1软件自动处理，每个样本作三次平行检测，取平均值作为该样本的最终定量。数据应用SPSS统计软件进行处理，对组间基因表达水平的差异采用独立样本的T检验，调用本实验室G72基因单核苷酸多态性（SNPs）资料，用单因素方差分析的方法分析SNP与基因表达水平的关联性。结果 1.检测得到G72基因在对照组中的表达量为0.0586±0.0114amol/ng cDNA, 在精神分裂症患者组中的表达量为0.0498±0.0121amol/ng cDNA。2.经显著性检验， G72基因的表达水平在病例和对照组间差异无统计学意义，t=-0.512，df138，P=0.609，95%CI:-4.258~2.506。3.单因素方差分析结果显示，rs947267位置上的SNP与该基因的表达水平无相关，F=0.355，df2，χ2=0.703；而rs2181953位置上的SNP与G72基因表达水平相关联，F=6.275，df2，χ2=0.004。A/A基因型的患者基因表达水平显著高于其他基因型。结论：精神分裂症患者G72基因的表达量总体上较正常人并无显著变化，但rs2181953位置上的基因型会影响精神分裂症患者该基因的表达。     

独生子女精神分裂症患者父母心理状况调查

目的探讨独生子女首发精神分裂症患者父母的心理健康状况。方法采用SCL-90症状自评量表评定80例首发精神分裂症的独生子女患者父母．所得资料与中国常模比较。结果精神分裂症患者父母的阳性项目数高于全国常模（P〈0．01），各个因子分与常模比较．均明显高于常模（P〈0．05），尤以躯体化、强迫、抑郁、焦虑、人际关系、敌对因子显著。结论精神分裂症患者严重影响了父母的工作、生活，造成父母心理障碍，医护人员在对患者进行治疗时，还应注重对患者父母认知、情绪和行为的改善，提高其社会适应能力，改善对待患者的态度。     

精神分裂症恢复期患者及家属家庭干预的对照研究

目的：以康复期出院精神分裂症患者和家属为对象，定期复诊进行家庭干预并对照研究。方法：干预组68例，对照组52例，采用BPRS评定；干预组家属74人，对照组家属65人，采用SCL－90评定。结果：6个月后干预组患者BPRS和入组时对照比较均有显著性差异（P＜0．01），说明干预组患者的精神症状，不良情绪及社会功能明显好转，入组时两组家属SCL－90评定与常模对照比较，均有明显差异（P＜0．05或0．01），经干预后干预组与全国常规比较无显著性差异（P＞0．05），说明患者家属普遍存在心理障碍，经干预后家属心理状况明显改善。结论：对康复期病人及家属进行门诊家庭干预，是有效的康复方法，值得推广应用。     

心理健康对精神分裂症患者认知功能的影响

目的观察心理健康对精神分裂症患者认知功能的影响。方法采用入院顺序分层随机法，将120例慢性精神分裂症患者分为研究组（心理健康＋奋乃静）和对照组（单用奋乃静）治疗。在治疗前，治疗后4、8、12周末分别以阳性症状和阴性症状量表（PNASS？评定疗效，用韦氏成人智力量表（WAIS—R）、韦氏记忆量表（WMS）和威斯康星卡片分类测验（wCST）评定治疗前后患者认知功能的改变。结果治疗12周后，研究组的言语量表、操作量表、全量表和记忆量表分分别为84．97±3．73、80．41±5．93、83．37±5．81、77．26±13．31；对照组分别为75．41±3．95、72．43±5．56、75．87±5．34、72．15±13．19，两组有显著差异（P〈0．01）。PANSS总分、阴性因子分比治疗前明显降低。结论心理健康治疗对精神分裂症患者认知功能有明显改善。